After Shire reported headline data for its Premiplex drug, Bernstein says that the drug missed its primary endpoint of reducing ROP in premature babies but did meet two secondary endpoints: reduction of rates of severe bronchopulmonary dysplasia, a chronic lung disease and severe intraventricular haemorrhage. The firm says that the data is "intriguing," and it reports that the expert with whom it spoke was upbeat about the results. The firm thinks the drug's sales could easily reach $2.5B, and it keeps a $222 price target and Outperform rating on the shares.